Fibrocell Science Inc (FCSC) : Context Capital Management reduced its stake in Fibrocell Science Inc by 42.72% during the most recent quarter end. The investment management company now holds a total of 15,300 shares of Fibrocell Science Inc which is valued at $42,228 after selling 11,410 shares in Fibrocell Science Inc , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Fibrocell Science Inc makes up approximately 0.37% of Context Capital Management’s portfolio.
Fibrocell Science Inc closed down -0.04 points or -1.45% at $2.72 with 1,32,495 shares getting traded on Monday. Post opening the session at $2.79, the shares hit an intraday low of $2.64 and an intraday high of $2.81 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa sold out all of its stake in FCSC during the most recent quarter. The investment firm sold 2,967 shares of FCSC which is valued $9,850. Simplex Trading sold out all of its stake in FCSC during the most recent quarter. The investment firm sold 8,068 shares of FCSC which is valued $21,703. Franklin Street Advisors Inc Nc added FCSC to its portfolio by purchasing 50,000 company shares during the most recent quarter which is valued at $134,500. Fibrocell Science Inc makes up approx 0.03% of Franklin Street Advisors Inc Nc’s portfolio.
Many Wall Street Analysts have commented on Fibrocell Science Inc. Shares were Reiterated by Wedbush on Mar 11, 2016 to “Neutral” and Lowered the Price Target to $ 4 from a previous price target of $6 .
Fibrocell Science Inc. (Fibrocell) is an autologous cell therapy company focused on developing treatments for rare and serious skin and connective tissue diseases. The Company’s lead orphan gene therapy program is in late-stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In addition to its gene therapy program the Company is pursuing the medical application of azficel-T for vocal cord scarring using its autologous fibroblast technology. The Company is also in pre-clinical development for its second gene therapy program for linear scleroderma. The Company’s collaboration with Intrexon Corporation a synthetic biology company includes using genetically modifying autologous fibroblast cells to express collagen VII that is missing or inactive from patients with RDEB.